Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EValuation of Clinical Outcome, Treatment Compliance and Tolerability of HumIRA (Adalimumab) in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries.

Next Previous
Trial Profile

EValuation of Clinical Outcome, Treatment Compliance and Tolerability of HumIRA (Adalimumab) in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms EviraEAST

Most Recent Events

  • 17 Jun 2017 Results (n=450) assessing efficacy of Adalimumab in ankylosing spondylitis patients in 5 Central and Eastern Europe countries, presented at the 18th Annual Congress of the European League Against Rheumatism
  • 20 Dec 2011 Actual patient number (809) added as reported by ClinicalTrials.gov.
  • 20 Dec 2011 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top